OC-096 Short-Term Results of Transversus Abdominis Release in Patients under Immunosuppression

Abstract Aim Immunosuppressive medication might increase the likelihood of wound morbidity, with possible higher rate surgical site infections (SSIs). We aim to identify short-term outcomes and hospital stay after incisional hernia repair transversus abdominis release (TAR) in patients versus without immunosuppression. Material & Methods All undergoing open abdominal wall uni-or bilateral TAR from January 2021 through November 2022 were identified using a prospectively maintained database. Minimum follow-up was 30 days. Outcomes included 30-day SSIs, seroma rate, stay, early recurrence. Results Twenty-seven immunosuppressive 75 (mean age 59.0 ± 13.9 vs. 65.1 11.4, 74.1% 46.7% male, respectively). Median width 7.7 5.1 cm 7.9 4.3 respectively. At days follow-up, SSI 1/27 (3.7%) group under immunosuppression 5/75 (6.7%) (p = 0.575). Seroma 3/27 (11.1%) 12/75 (16.0%), respectively 0.539). Mean 6.0 3.6 vs 8.1 6.7 0.052). No recurrences detected either group. Conclusion Immunosuppression does not significantly risk complications release. There is trend towards shorter immunosuppression, possibly related reduced inflammatory response.